GALT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GALT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Galectin Therapeutics's goodwill for the quarter that ended in Mar. 2024 was $0.00 Mil.
The historical data trend for Galectin Therapeutics's Goodwill can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galectin Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Goodwill | Get a 7-Day Free Trial | - | - | - | - | - |
Galectin Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Goodwill | Get a 7-Day Free Trial | - | - | - | - | - |
A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.
Galectin Therapeutics (NAS:GALT) Goodwill Explanation
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.
It is calculated by dividing goodwill by total assets.
Galectin Therapeutics's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Goodwill-to-Asset (A: Dec. 2023 ) | = | Goodwill | / | Total Assets |
= | 0 | / | 28.2 | |
= |
Galectin Therapeutics's Goodwill-to-Asset Ratio for the quarter that ended in Mar. 2024 is calculated as
Goodwill-to-Asset (Q: Mar. 2024 ) | = | Goodwill | / | Total Assets |
= | 0 | / | 25.89 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
Thank you for viewing the detailed overview of Galectin Therapeutics's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.
Kary Eldred | director | 2121 RINGWOOD AVENUE, SAN JOSE CA 95131 |
Kevin D Freeman | director | 712 LAKEWAY DRIVE, KELLER TX 76248 |
Zordani Richard A. Jr. | director | 467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047 |
10x Fund, L.p. | 10 percent owner | 1099 FOREST LAKE TERRACE, NICEVILLE FL 32578 |
Elissa J. Schwartz | director | 235 SW CHURCH ST., PULLMAN WA 99163 |
Gilbert F Amelio | director | 5835 STRASBOURG COURT, ---, RENO NV 89511 |
Richard E Uihlein | director, 10 percent owner | 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158 |
Pol F Boudes | officer: Chief Medical Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Joel Lewis | director | 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158 |
Gilbert S Omenn | director | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Harold H. Shlevin | director, officer: Chief Executive Officer | C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071 |
Jack W Callicutt | officer: Chief Financial Officer | 75 FIFTH STREET NW STE. 313, ATLANTA GA 30308 |
Marc Rubin | director | C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080 |
James C Czirr | director | 4908 SOUTH ASHTON COURT, SPOKANE WA 99223 |
Peter G Traber | director, officer: President and CEO | 430 THAMER LANE, HOUSTON TX 77025 |
From GuruFocus
By sperokesalga sperokesalga • 04-27-2023
By PurpleRose PurpleRose • 07-12-2022
By Marketwired • 09-11-2023
By GuruFocusNews GuruFocusNews • 07-05-2022
By Marketwired • 08-14-2023
By PurpleRose PurpleRose • 08-15-2022
By Stock market mentor Stock market mentor • 01-05-2023
By sperokesalga sperokesalga • 05-15-2023
By Value_Insider Value_Insider • 11-01-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.